Detalhe da pesquisa
1.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Lancet
; 400(10348): 273-282, 2022 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871814
2.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 400(10356): 908-919, 2022 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36116481
3.
Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results.
Ann Allergy Asthma Immunol
; 131(5): 598-605.e3, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506846
4.
Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma.
Ann Allergy Asthma Immunol
; 130(6): 784-790.e5, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36906262
5.
Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis.
J Allergy Clin Immunol
; 150(6): 1517-1524, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041655
6.
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
J Allergy Clin Immunol
; 149(3): 977-987.e14, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34403658
7.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 397(10290): 2169-2181, 2021 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023009
8.
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
Allergy
; 77(7): 2175-2184, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34773261
9.
Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3).
Ann Allergy Asthma Immunol
; 129(5): 592-604.e5, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35843520
10.
Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
Ann Allergy Asthma Immunol
; 129(4): 467-474.e3, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728746
11.
Differing perceptions of asthma control and treatment effectiveness by patients with severe asthma and treating subspecialists in the United States.
J Asthma
; 59(9): 1859-1868, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34374622
12.
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.
J Allergy Clin Immunol
; 148(3): 790-798, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33872652
13.
Omalizumab response in patients with asthma by number and type of allergen.
Ann Allergy Asthma Immunol
; 127(2): 223-231, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33838339
14.
Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
Ann Allergy Asthma Immunol
; 127(5): 579-587.e1, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34273485
15.
Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
Ann Allergy Asthma Immunol
; 125(3): 294-303.e1, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32304877
16.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
J Am Acad Dermatol
; 82(2): 377-388, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31374300
17.
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Lancet
; 387(10013): 40-52, 2016 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26454361
18.
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.
Respir Res
; 17: 29, 2016 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993628
19.
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
J Am Acad Dermatol
; 75(3): 506-515, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27268421
20.
Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma.
J Asthma Allergy
; 17: 441-448, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38745837